~~<i id='309595BC62'><strike id='309595BC62'><tt id='309595BC62'><pre id='309595BC62'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

fashion

author：fashion 2025-10-02 22:26:30 - browse：291

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Eli Lilly said Tuesday that it will purchase DICE Therapeutics, a small company developing an experimental pill to treat psoriasis, for $2.4 billion in cash.

The deal price of $48 per share represents a 42% premium to DICE’s closing price Friday.

“In combination with its novel technology and expertise in drug discovery, DICE’s talented workforce and passion for innovation will enhance our efforts to make life better for people living with devastating autoimmune diseases,” Patrik Jonsson, executive vice president, president of Lilly Immunology and Lilly USA, chief customer officer, said in a statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： What will Novo Nordisk's VC do with its influx of cash?

focus

entertainment

focus

explore

AUkrainiancadetholdsanartificialflowerinthecoloroftheUkrainianflagontheoutskirtsofKyiv.SERGEISUPINSK

WSS

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Intarcia’s device

Senate HELP committee spars over health care workforce policies

Experts study whether long Covid risk adds up with each reinfection

CDC picks Alphabet's Verily for wasterwater surveillance contract

It's been 20 years since Dolly the sheep. Where's my clone?

focus

fashion

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Flu, Covid vaccination rates decline, new survey data show

Sports medicine is finally prioritizing gender equality

Medical student insurance fails on mental health care coverage

Anesthesiologist group: stop taking Ozempic before surgery

How Vertex's cystic fibrosis drug is changing patients' lives

Medical leaders decry Supreme Court decision on affirmative action

Second xenotransplant done with gene

Virginia high school admissions case could be legal follow

Hearing on Medicare drug price negotiation gets unusually heated

entertainment

It's been 20 years since Dolly the sheep. Where's my clone?

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Biotech stock slump in 2023: awaiting the turnaround

CommonSpirit Health keeps growing, even as it loses money

2023 Nobel Prize in Medicine goes to Karikó and Weissman

Microbiome research is starting to find links to chronic diseases

entertainment

entertainment

focus

explore